Two Pharma Giants Dominate GLP-1 Citations Across Major AI Platforms

The Rising Dominance of GLP-1 in AI Citations

In a remarkable transformation within the weight loss and metabolic health sector, recent findings reveal that two pharmaceutical powerhouses, Novo Nordisk and Eli Lilly, dominate GLP-1 citations across popular AI tools like ChatGPT, Claude, and Perplexity. According to the latest Weight Loss & Metabolic Health AI Visibility Index 2026 from 5W Public Relations, these two companies control nearly 100% of GLP-1 mentions in contexts where Americans seek information about weight loss.

Understanding GLP-1 and Its Market Influence

GLP-1 receptor agonists—drugs that mimic the effects of the natural GLP-1 hormone in the body—are pivotal in managing chronic weight issues. The drugs notably include:

- Wegovy
- Zepbound
- Ozempic
- Mounjaro
- Saxenda

These brands collectively account for about 57% of all citations in the weight management category. Wegovy alone leads with an impressive 19%, showing not just market demand but heavy reliance on these pharmaceutical solutions over traditional weight loss methods and dietary supplements.

Unquestionably, Novo Nordisk and Eli Lilly are the only companies providing FDA-approved options for long-term weight management along with substantiated clinical trial data such as the STEP, SURMOUNT, and SELECT studies, often referenced by AI models.

Analysis of AI Citation Landscape

According to the index, a limited number of brands dominate the AI citation landscape:
1. Wegovy – 19.0%
2. Zepbound – 16.0%
3. Ozempic – 13.0%
4. Mounjaro – 7.0%
5. Noom – 7.0%

The data shows significant shifts, where both emerging and traditional competitors are struggling to maintain visibility. For instance, legacy brands such as Jenny Craig and Nutrisystem are increasingly perceived merely as alternatives